Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K190675
    Date Cleared
    2019-05-17

    (63 days)

    Product Code
    Regulation Number
    862.1215
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Dimension EXL High-Sensitivity Troponin I (TNIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human plasma using the Dimension EXL integrated chemistry system with LOCI module. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).

    Device Description

    The Dimension EXL TNIH assay is a homogeneous, sandwich chemiluminescent immunoassay based on LOCl® technology. The LOCI reagents include two synthetic bead reagents and two biotinylated anti-cardiac troponin I monoclonal antibody fragments. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with a third anticardiac troponin I monoclonal antibody and contains chemilyminescent dve. Sample is incubated with Chemibeads and biotinylated antibodies to form bead-cardiac troponin Ibiotinylated antibody sandwiches. Sensibeads are added and bind to form bead-pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the cardiac troponin I concentration in the sample. Lithium heparin plasma specimens may be used. The reagent is stored unopened at 2 -8 °C, is stable sealed on system for 30 days and opened on the system for 7 days. Calibration is performed every 21 days for a reagent lot.

    AI/ML Overview

    Here's a summary of the acceptance criteria and study details for the Dimension EXL High-Sensitivity Troponin I (TNIH) Assay, extracted from the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Performance MetricAcceptance Criteria (implicit from compliance)Reported Device Performance
    Limit of Blank (LoB)Consistency with claim of 1.1 pg/mL1.0 pg/mL
    Limit of Detection (LoD)Consistency with claim of 2.7 pg/mL1.0 - 1.8 pg/mL
    Limit of Quantitation (LoQ)CV ≤ 20.0%1.1 pg/mL (Lot-1), 2.1 pg/mL (Lot-2), 2.3 pg/mL (Lot-3). Claimed LoQ of 4.0 pg/mL. (The LoQ of 4.0 pg/mL is explicitly stated to be consistent with the data, implying it met the 20% CV criteria).
    10% CV LimitCV ≤ 10.0%3.2 pg/mL (Lot-1), 5.3 pg/mL (Lot-2), 5.8 pg/mL (Lot-3). Claimed 10% CV limit of 12.0 pg/mL. (The 10% CV limit of 12.0 pg/mL is explicitly stated to be consistent with the data, implying it met the 10% CV criteria).
    Precision (Repeatability %CV)All precision goals were met (specific target not provided, but values shown are low)Plasma 1: 2.3%, Plasma 2: 2.0%, Plasma 3: 1.8%, QC: 2.0%
    Precision (Within-Lab %CV)All precision goals were met (specific target not provided, but values shown are low)Plasma 1: 6.0%, Plasma 2: 2.9%, Plasma 3: 3.0%, QC: 3.3%
    Linearityp-values of nonlinear terms > 0.05 OR allowable bias ≤ 10% or 4 pg/mLConfirmed linearity from 4.0 - 25,000.0 pg/mL.
    Interferences (Bias)Bias exceeding 10% is considered interference.Hemoglobin: 20,000 pg/mL)
    Open Well Stabilityp-value of regression slope ≥ 0.05 OR drift ≤ LoQ or ≤ 10% (up to 20,000 pg/mL), ≤ 13% (> 20,000 pg/mL)Stability of reagents opened onboard the instrument was 7 days per well set. (This implies it met the acceptance criteria for 7 days).
    Sample StabilityLower bound of 95% CI of regression line ≤ -10% AND all data points bias ≤ -20% vs time zeroSeparated samples stable for 8 hours at room temperature, 24 hours at 2-8°C, up to 40 days at or below -20°C (non-frost free), and up to 1 year at or below -70°C. (This implies these storage conditions met the specified bias criteria).
    99th Percentile Expected ValuesDetermined using non-parametric statistical method (CLSI EP28-A3c).Overall: 60.4 pg/mL (90% CI: 43.2 to 81.3); Female: 51.4 pg/mL (90% CI: 35.6 to 109.2); Male: 76.2 pg/mL (90% CI: 42.3 to 117.0). No statistical basis for using separate values based on gender or sample type.
    Clinical PerformanceNo explicit quantitative acceptance criteria provided in the extract, but the data presented supports its diagnostic utility.Pooled Gender (60.4 pg/mL cutoff): Sensitivity ranging from 78.3% (0-
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1